
    
      -  Each treatment cycle lasts 21 days and patients will participate in a least 4 cycles,
           but no more than 6 cycles of treatment.

        -  Patients will receive cytoxan (cyclophosphamide) and epirubicin intravenously on day 1
           of each treatment cycle. On days 4-17 of each cycle, patients will take capecitabine
           orally twice a day.

        -  While on the study patients will be required to complete a diary of they capecitabine
           treatment.

        -  Blood tests will be performed each week along with surveys at the beginning of the trial
           and certain follow-up visits to evaluate the patient's experience with the oral
           chemotherapy.

        -  Patients will be on the treatment for 12-18 weeks depending upon whether or not the
           disease progresses or the patient develops inacceptable side effects.
    
  